Related Experiment Video
Updated: Jan 9, 2026
An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
Published on: January 26, 2019
Healthcare costs and resource utilization for acute respiratory syncytial virus pediatric hospitalizations in Canada:
Nirma Khatri Vadlamudi1,2, Kyle Gomes1, Ethan Chow1
1Vaccine Evaluation Center, BC Children's Hospital Research Institute, University of British Columbia, Vancouver, British Columbia, Canada.
Insights
Respiratory syncytial virus (RSV) significantly impacts infants, causing numerous hospitalizations and high healthcare costs. This study highlights an urgent need for prevention strategies, especially for infants under six months old, to reduce the burden on Canadian healthcare systems.
Area of Science:
- Pediatric Infectious Diseases
- Public Health Surveillance
- Health Economics
Background:
- Respiratory syncytial virus (RSV) is a leading cause of severe respiratory illness like bronchiolitis and pneumonia in children.
- Infants are particularly vulnerable to RSV, facing significant health risks and hospitalization rates.
Purpose of the Study:
- To determine the overall and age-specific incidence of RSV-associated hospitalizations in Canadian children.
- To analyze healthcare resource utilization and associated costs for RSV hospitalizations across different pediatric age groups.
Main Methods:
- Utilized national administrative data (CIHI) and active surveillance (IMPACT) from November 2017 to April 2023.
- Included children aged 0-16 years with RSV diagnoses, estimating incidence, length of stay, ventilation use, and costs.
- Population denominators were sourced from Statistics Canada for incidence calculations.
Main Results:
- Estimated 29,277 RSV hospitalizations, averaging 5831 annually pre-pandemic.
- Infants under 6 months accounted for 44.6% of cases and 49.0% of annual costs (average $66.3M CAD).
- RSV incidence in infants <6 months increased significantly from 1250 to 2393 per 100,000.
Conclusions:
- High RSV hospitalization rates in infants <6 months underscore the critical need for targeted prevention strategies.
- Implementing effective prevention measures can alleviate substantial health and economic burdens on the Canadian healthcare system.
Background:
Respiratory syncytial virus (RSV) is a major cause of bronchiolitis and pneumonia in pediatric populations, especially in infancy. This study aims to assess overall and age-specific incidence of RSV-associated hospitalization and healthcare resource use throughout childhood in Canada.
Methods:
Data were retrieved from a national administrative dataset, which captured hospitalizations with International Classification of Diseases (ICD) codes, tenth revision from participating Canadian hospitals (Canadian Institute for Health Information, CIHI), and from an active surveillance program in tertiary care pediatric hospitals (the Canadian Immunization Program ACTive, IMPACT). Children aged 0-16 years with RSV in November 2017 through April 2023 were eligible. We estimated overall and age-specific RSV hospitalization incidence, healthcare resource use (length of stay, mechanical ventilation use), and costs by age group (0-5, 6-11, and 12-23 months, and 2-4 years, 5-9 years, 10-16 years). Costs were adjusted to 2022 Canadian dollars (CAD). The population denominator for age-specific RSV incidence estimates was retrieved from Statistics Canada.
Findings:
An estimated 29,277 RSV hospitalizations occurred, with an average of 5831 cases/year in pre-pandemic years (November 2017-June 2020). Infants aged <6 months old accounted for 13,055 (44.6%) of cases for study duration (November 2017-April 2023). RSV incidence among infants aged <6 months increased from 1250 per 100,000 in November 2017-June 2018 to 2393 per 100,000 in July 2022-April 2023. The average annual cost of RSV was $66,267,950 CAD. Infants <6 months old accounted for 49.0% ($32,471,296 CAD) of annual average RSV healthcare costs.
Interpretation:
Although RSV occurs throughout childhood, the high RSV hospitalization incidence in infants younger than 6 months of age highlights an urgent need for prevention strategies in this population to alleviate the health burden in this population and economic burden on healthcare systems.
Funding:
This surveillance activity is conducted as part of the Canadian Immunization Monitoring Program Active (IMPACT), a national surveillance initiative managed by the Canadian Paediatric Society (CPS) and conducted by the IMPACT network of pediatric investigators. Funding for RSV surveillance was provided by the Public Health Agency of Canada; funding for RSV economic burden analyses was provided by Sanofi and AstraZeneca.
More Related Videos
Related Concept Videos
01:29Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
01:21Acute Respiratory Failure-I
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
01:21Acute Respiratory Failure-II
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
01:30Acute Respiratory Failure-III
01:31Common Respiratory Disorders
Upper respiratory disorders impact the airways above the vocal cords, encompassing areas like the nose, sinuses, and throat. Various conditions fall under this category, including the common cold and allergic rhinitis. These disorders can stem from several causes,...
01:23Acute Respiratory Failure-IV